Production of cytokines by bone marrow cells obtained from patients with multiple myeloma - PubMed (original) (raw)
. 1989 Sep;74(4):1266-73.
Affiliations
- PMID: 2475182
Free article
Production of cytokines by bone marrow cells obtained from patients with multiple myeloma
A Lichtenstein et al. Blood. 1989 Sep.
Free article
Abstract
Previous work with continuously cultured multiple myeloma lines suggested that cytokine production by tumor cells may mediate some of the medical complications of this disease. To further investigate this issue, we assayed freshly obtained bone marrow (BM) cells from myeloma patients for the in vitro production of cytokines and the presence of cytokine RNA. Production of cytokine protein was assessed by bioassays with the aid of specific neutralizing anticytokine antibodies. These assays detected interleukin-1 (IL-1) and tumor necrosis factor (TNF) secretion by myeloma BM cells, which was significantly greater than secretion from similarly processed BM cells of control individuals. In contrast, lymphotoxin and interleukin-2 (IL-2) production could not be detected. The levels of IL-1 and TNF produced in vitro peaked at 24 hours of culture and correlated with stage and the presence (or absence) of extensive osteolytic bone disease. Northern blot analysis demonstrated the presence of IL-1 beta and TNF RNA in uncultured myeloma BM cells but no detectable IL-1 alpha or lymphotoxin RNA. In addition, the amount of cytokine RNA correlated with protein production, being significantly greater in patients' BM cells than in control marrow. These data suggest a role for IL-1 beta and/or TNF in the pathophysiology of multiple myeloma and argue against a role for lymphotoxin or IL-2.
Similar articles
- Production of interleukin-1 by bone marrow myeloma cells.
Cozzolino F, Torcia M, Aldinucci D, Rubartelli A, Miliani A, Shaw AR, Lansdorp PM, Di Guglielmo R. Cozzolino F, et al. Blood. 1989 Jul;74(1):380-7. Blood. 1989. PMID: 2665838 - Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells.
Garrett IR, Durie BG, Nedwin GE, Gillespie A, Bringman T, Sabatini M, Bertolini DR, Mundy GR. Garrett IR, et al. N Engl J Med. 1987 Aug 27;317(9):526-32. doi: 10.1056/NEJM198708273170902. N Engl J Med. 1987. PMID: 3497347 - Production of interleukin 1 beta, a potent bone resorbing cytokine, by cultured human myeloma cells.
Yamamoto I, Kawano M, Sone T, Iwato K, Tanaka H, Ishikawa H, Kitamura N, Lee K, Shigeno C, Konishi J, et al. Yamamoto I, et al. Cancer Res. 1989 Aug 1;49(15):4242-6. Cancer Res. 1989. PMID: 2787204 - Osteoclast function in Paget's disease and multiple myeloma.
Roodman GD. Roodman GD. Bone. 1995 Aug;17(2 Suppl):57S-61S. doi: 10.1016/8756-3282(95)00179-h. Bone. 1995. PMID: 8579899 Review. - Bone marrow microenvironment and the progression of multiple myeloma.
Caligaris-Cappio F, Gregoretti MG, Merico F, Gottardi D, Ghia P, Parvis G, Bergui L. Caligaris-Cappio F, et al. Leuk Lymphoma. 1992 Sep;8(1-2):15-22. doi: 10.3109/10428199209049813. Leuk Lymphoma. 1992. PMID: 1493467 Review.
Cited by
- A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma.
Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I. Noonan K, et al. Blood. 2010 Nov 4;116(18):3554-63. doi: 10.1182/blood-2010-05-283895. Epub 2010 Jul 27. Blood. 2010. PMID: 20664052 Free PMC article. - Bioinformatics analyses of differentially expressed genes associated with bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.
Sun J, Wen X, Jin F, Li Y, Hu J, Sun Y. Sun J, et al. Onco Targets Ther. 2015 Sep 22;8:2681-8. doi: 10.2147/OTT.S88463. eCollection 2015. Onco Targets Ther. 2015. PMID: 26445550 Free PMC article. - Glycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition?
da Fonseca LM, da Silva VA, Freire-de-Lima L, Previato JO, Mendonça-Previato L, Capella MA. da Fonseca LM, et al. Front Oncol. 2016 Jun 22;6:158. doi: 10.3389/fonc.2016.00158. eCollection 2016. Front Oncol. 2016. PMID: 27446804 Free PMC article. Review. - The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death.
El-Mesery M, Rosenthal T, Rauert-Wunderlich H, Schreder M, Stühmer T, Leich E, Schlosser A, Ehrenschwender M, Wajant H, Siegmund D. El-Mesery M, et al. Cell Death Dis. 2019 Aug 13;10(8):611. doi: 10.1038/s41419-019-1860-2. Cell Death Dis. 2019. PMID: 31406107 Free PMC article. - Multiple myeloma/hypercalcemia.
Oyajobi BO. Oyajobi BO. Arthritis Res Ther. 2007;9 Suppl 1(Suppl 1):S4. doi: 10.1186/ar2168. Arthritis Res Ther. 2007. PMID: 17634143 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical